Ring Therapeutics presented new data on its Vector Conjugate platform and VectorBricks manufacturing technology at the 29th Annual American Society of Gene & Cell Therapy conference. The company showcased Vector Oligonucleotide Conjugates (VOCs), which deliver significantly more payload than antibodies for oligonucleotide therapy. The poster presentation demonstrated successful VOC manufacturing through direct siRNA conjugation onto recombinant capsid proteins, with targeting ligand functionalisation enhancing potency in vitro. The oral presentation outlined VectorBricks, a modular in vitro assembly platform that achieved high-titer production comparable to traditional monoclonal antibody processes at 50-litre scale. Ring's platform aims to address payload capacity limitations and manufacturing complexity in targeted therapeutics. The technology can package diverse payloads including small molecules, siRNA and DNA, potentially expanding oligonucleotide therapy beyond rare genetic disorders.

Ring Therapeutics presented new data at the ASCGT Conference in New Orleans showing that its AnelloVectors - produced using its AnelloBricks(TM) in vitro assembly technology - have successful infectivity and expression of AnelloVectors.